Further studies aiming at elucidating the regulation of angiogenesis inhibitors by pVHL will be beneficial for the development of new anti-angiogenic and anti-tumour therapies for ccRCC. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.